SonoThera has raised $125 million to advance its ultrasound-based, non-viral gene therapy platform into the clinic. The funding round is led by Vida Ventures, with participation from large pharma venture arms including UCB, Bayer, Otsuka, and Johnson & Johnson. The company plans to move two lead programs toward clinical evaluation: Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease. SonoThera’s approach relies on microbubbles to enhance delivery, aiming to avoid limitations seen in viral vectors such as liver toxicity risk and immune recognition that can limit dosing. The financing underscores how established gene-therapy investors are continuing to back alternative delivery technologies that could expand use cases beyond rare disease populations.